Abstract Reparative hepatocyte replication is impaired in chronic liver disease, contributing to disease progression; however, the underlying mechanism remains elusive. Here, we identify Map3k14 (also known as NIK) and its substrate Chuk (also called IKKa) as unrecognized suppressors of hepatocyte replication. Chronic liver disease is associated with aberrant activation of hepatic NIK pathways. We found that hepatocyte-specific deletion of Map3k14 or Chuk substantially accelerated mouse hepatocyte proliferation and liver regeneration following partialhepatectomy. Hepatotoxin treatment or high fat diet feeding inhibited the ability of partialhepatectomy to stimulate hepatocyte replication; remarkably, inactivation of hepatic NIK markedly increased reparative hepatocyte proliferation under these liver disease conditions. Mechanistically, NIK and IKKa suppressed the mitogenic JAK2/STAT3 pathway, thereby inhibiting cell cycle progression. Our data suggest that hepatic NIK and IKKa act as rheostats for liver regeneration by restraining overgrowth. Pathological activation of hepatic NIK or IKKa likely blocks hepatocyte replication, contributing to liver disease progression.
Introduction
The liver is an essential metabolic organ that experiences metabolic stress during fasting, refeeding, and overnutrition states (Rui, 2014) . The liver is also responsible for detoxifications of endogenous and exogenous toxic substances, thus being frequently exposed to harmful insults. Dietary hepatotoxins and gut microbiota-derived toxic substances are transported to the liver through the enterohepatic circulation, further increasing risk for liver injury. To compensate for hepatocyte loss, the liver evolves a powerful regenerative ability to maintain its homeostasis (Michalopoulos, 2017) . After 70% of partial hepatectomy (PHx), rodents are able to regain normal liver mass within a week via reparative hepatocyte replications (Miyaoka et al., 2012) . Nevertheless, hepatocyte proliferation is severely inhibited in chronic liver diseases, including nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease, and chronic exposures to hepatotoxins (Richardson et al., 2007; Inaba et al., 2015; Sancho-Bru et al., 2012; Michalopoulos, 2013) . Impairment in hepatocyte replications considerably precipitates liver disease progression; however, the underlying mechanism responsible for defective hepatocyte replications remains poorly understood.
In response to liver injury induced by PHx, numerous growth factors and cytokines are secreted and delivered to hepatocytes where they stimulate hepatocyte proliferation by activating multiple mitogenic pathways, including the Janus kinase 2 (JAK2)/STAT3, MAPK, PI 3-kinase, and NF-kB pathways (Michalopoulos, 2017) . In contrast, TGFb1 and interferon-g inhibit hepatocyte proliferation, thereby preventing liver from overgrowth (Michalopoulos, 2013; Sato et al., 1993; Wu et al., 2015) . Liver regeneration is fine-tuned by a balance between positive and negative regulators. We postulated that in chronic liver disease, the negative branch might be predominant and overcome the positive branch, leading to pathological suppression of hepatocyte proliferation and liver regeneration. However, intracellular pathways conferring hepatocyte proliferation inhibition remain elusive. In search for inhibitory pathways, we identified Map3k14, also called NF-kB-inducing kinase (NIK), and its substrate Chuck, also referred to as IkB kinase a (IKKa).
NIK is a Ser/Thr kinase known to activate the noncanonical NF-kB2 pathway (Sun, 2012) . It phosphorylates and activates IKKa (Xiao et al., 2001 ). IKKa in turn phosphorylates the precursor of NFkB2 p100, resulting in generation of the p52 form of NF-kB2 (Sun, 2012; Xiao et al., 2001 ). Mature p52 is translocated into the nucleus to activate target genes. We previously reported that metabolic stress, oxidative stress, hepatotoxins, and cytokines stimulate hepatic NIK (Sheng et al., 2012; Jiang et al., 2015) . Importantly, hepatic NIK is aberrantly activated in both mice and humans with NAFLD or alcoholic liver disease (Sheng et al., 2012; Shen et al., 2014) . Hepatocellular stress and liver inflammation, which are associated with chronic liver disease, likely activate hepatic NIK. These observations prompted us to test the hypothesis that hepatic NIK/IKKa pathways cell-autonomously inhibit hepatocyte proliferation. In this work, we characterized hepatocyte-specific NIK (NIK Dhep ) and IKKa (IKKa Dhep ) knockout mice, and examined reparative hepatocyte replications using PHx models. We found that the NIK/IKKa pathway suppresses reparative hepatocyte proliferation at least in part by inhibiting the JAK2/STAT3 pathway. This work unveils unrecognized crosstalk between the NIK/ IKKa and the JAK2/STAT3 pathways involved in regulating liver regeneration.
Results

Hepatocyte-specific ablation of NIK accelerates liver regeneration
To assess the role of hepatic NIK in reparative hepatocyte proliferation, we performed 70% of PHx on mice at 8 weeks of age following the established protocols (Mitchell and Willenbring, 2008) . NIK Dhep mice were generated by crossing Map3k14 flox/flox (referred to as NIK f/f ) mice with AlbuminCre drivers . Proliferating cells were detected by immunostaining liver sections with antibody against Ki67, a cell proliferation marker ( Figure 1A) . Baseline hepatocyte proliferation rates were low and comparable between NIK Dhep and NIK f/f mice ( Figure 1B) . Number of liver proliferating Ki67 + cells markedly increased within 48 hr following PHx, and Ki67 + cells were 85% higher in NIK Dhep relative to NIK f/f mice ( Figure 1B ). In line with these observations, the number of liver BrdU-labelled proliferating cells was also substantially higher in NIK Dhep than in NIK f/f mice ( Figure 1C) . Liver cell proliferation rates declined in both NIK Dhep and NIK f/f mice after 48 hr postPHx, and became comparable between these two groups at 96 hr post-PHx ( Figure 1B ).
To verify hepatocytes proliferating, we costained liver sections with anti-Ki67 and anti-HNF4a (a hepatocyte marker) antibodies, or with anti-Ki67 and anti-F4/80 (a Kupffer cell/macrophage marker) antibodies. HNF4a + hepatocytes accounted for 96% of Ki67 + proliferating cells in NIK Dhep mice at 48 hr post-PHx ( Figure 1D ,F) while F4/80 + Kupffer cells/macrophages for <4% of Ki67 + cells ( Figure 1E ,F). These data indicate that hepatic NIK is an intrinsic suppressor of hepatocyte proliferation.
We also examined the effect of NIK deficiency on hepatocyte death using TUNEL assays. The number of liver TUNEL + apoptotic cells was slightly lower in NIK Dhep relative to NIK f/f mice, but the difference was not statistically significant ( Figure 1G ). Plasma alanine aminotransferase (ALT) activity, a liver injury index, was comparable between NIK Dhep and NIK f/f mice either under basal conditions or after PHx ( Figure 1H ). Thus, accelerated hepatocyte proliferation cannot be explained by changes in liver injury in NIK Dhep mice.
To further confirm the role of hepatic NIK in liver regeneration, we assessed liver to body weight ratios at 2 and 4 days post-PHx. Consistently, liver/body weight ratios were significantly higher in NIK Dhep than in NIK f/f mice at 4 days following PHx ( Figure 1I ). Of note, liver/body weight ratios Liver/body weight ratios (%) Figure 1 . Hepatocyte-specific ablation of NIK accelerates reparative hepatocyte proliferation. NIK f/f (n = 7) and NIK Dhep (n = 7) male mice (8 weeks)
were subjected to PHx, and livers were harvested 48 hr or 96 hr later. were similar between these two groups at 2 days post-PHx. One possible explanation is that a 2 day period may be too short for newly-generated hepatocytes to grow in size large enough to increase liver weight. To determine whether NIK inhibits hepatocyte cell cycle progression, we measured the levels of cyclin D1, which is believed to drive hepatocyte proliferation following PHx (Michalopoulos, 2013) . Hepatic cyclin D1 levels were undetectable in both NIK Dhep and NIK f/f mice under basal conditions, and were markedly increased by PHx (Figure 2A) . Importantly, hepatic cyclin D1 levels were significantly higher in NIK Dhep than in NIK f/f mice (Figure 2A,B) . Collectively, these results support the notion that hepatic NIK may act as an intrinsic rheostat for liver homeostasis by restraining liver overgrowth.
The role of NF-kB1, MAPK, and PI 3-kinase pathways in NIK-induced suppression of hepatocyte proliferation
We next sought to interrogate the molecular mechanism of the NIK action. Expression of liver NIK rapidly increased within 12 hr following PHx, but declined at 3 days post-PHx ( . The NF-kB1, MAPK, and PI 3-kinase pathways are known to be involved in mediating PHx-stimulated liver regeneration (Michalopoulos, 2013; Wuestefeld et al., 2013; Pauta et al., 2016) . Unexpectedly, phosphorylation of hepatic IkBa, p65 (the NF-kB1 pathway), Akt (pSer473) (the PI 3-kinase pathway), ERK1/2, and JNK (the MAPK pathway) was comparable between NIK Dhep and NIK f/f mice at 4 hr post-PHx ( Figure 2C ). We also did not detect difference in hepatic levels of reactive oxygen species (ROS) or hepatic expression of cytokines between NIK Dhep and NIK f/f mice ( Figure 2D ,E). Therefore, NIK suppression of liver regeneration cannot be explained by the above pathways.
NIK suppresses the JAK2/STAT3 pathway JAK2 is known to phosphorylate and activate STAT3, which is believed to drive hepatocyte proliferation (Wang et al., 2011; Shi et al., 2017) . We postulated that NIK might suppress hepatocyte proliferation by inhibiting the JAK2/STAT3 pathway. Liver extracts were prepared at 4 hr post-PHx and immunoblotted with anti-phospho-JAK2 (pTyr1007/1008) or anti-phospho-STAT3 (pTyr705) antibodies. Phosphorylation of both JAK2 and STAT3 was significantly higher in NIK Dhep mice than in NIK To confirm that NIK directly inhibits the JAK2/STAT3 pathway, we transiently coexpressed JAK2 and STAT3 with NIK in HEK293 cells. In line with our previous reports (Rui and Carter-Su, 1999) , overexpressed JAK2 robustly autophosphorylated as well as phosphorylated STAT3 ( Figure 3B ). Strikingly, overexpression of NIK dramatically decreased tyrosine phosphorylation of both JAK2 and STAT3 ( Figure 3B ). Consistently, NIK was coimmunoprecipitated with JAK2 ( Figure 3C ). These data indicate that NIK binds to JAK2 and inhibits JAK2 activity, thereby suppressing the JAK2/STAT3 pathway.
Interleukin 6 (IL6) stimulates the JAK2/STAT3 pathway, which is required for reparative hepatocyte proliferation (Riehle et al., 2008; Cressman et al., 1996) . These observations prompted us to test if NIK negatively regulates the IL6/JAK2/STAT3 pathway. Mouse primary hepatocytes were transduced with NIK or b-galactosidase (b-gal) adenoviral vectors, followed by IL6 stimulation. IL6 robustly stimulated phosphorylation of STAT3 in b-gal-transduced, but not NIK-transduced, hepatocytes ( Figure 3D ). Collectively, these results unveil unrecognized crosstalk between NIK pathways and the JAK2/STAT3 pathway.
Hepatic IKKa suppresses liver regeneration following PHx
Given that IKKa acts downstream of NIK in the noncanonical NF-kB2 pathway, we reasoned that hepatic IKKa might also suppress liver regeneration. IKKa Dhep mice were generated by crossing Chuk flox/flox (referred to as IKKa f/f ) mice with albumin-Cre drivers (Liu et al., 2008) . We confirmed that IKKa expression was disrupted specifically in the liver but not brain, heart, kidney, skeletal muscle, and spleen in IKKa Dhep mice ( Figure 4A ). We performed PHx on IKKa f/f and IKKa Dhep male mice The following source data and figure supplements are available for figure 2:
IKKα
Source data 1. Hepatic NIK regulates hepatocyte cell cycle progression. at 8-9 weeks of age. The number of liver proliferating Ki67 + cells was significantly higher in IKKa Dhep than in IKKa f/f littermates at both 1 and 2 days post-PHx, and became similar between these two groups after 3 days following PHx ( Figure 4B ). HNF4a + hepatocytes accounted for the majority of proliferating cells ( Figure 4C ). Consistently, liver cyclin D1 levels were significantly higher in IKKa Dhep than in IKKa f/f mice ( Figure 4D ), while liver cell death was comparable between these two groups ( Figure 4E ). Consequently, liver to body weight ratios were significantly higher in IKKa Dhep relative to IKKa f/f mice at both 5 and 7 days post-PHx ( Figure 4F) . Notably, liver/body weight ratios were comparable between these two groups within 3 days following PHx, likely due to lack of sufficient time for hepatocytes to grow their mass as discussed before. These results indicate that deficiency Figure 5C ), and markedly decreased JAK2 autophosphorylation and the ability of JAK2 to phosphorylate STAT3 ( Figure 5D ).
To determine whether NIK suppresses the JAK2/STAT3 pathway via IKKa, we transduced primary hepatocytes from IKKa Dhep (IKKa-deficient) and IKKa f/f (wild type) mice with NIK or green fluorescent protein (GFP) adenoviral vectors, followed by IL6 stimulation. The ability of NIK to inhibit IL6-stimulated phosphorylation of STAT3 was significantly reduced in IKKa-deficient hepatocytes compared to wild type hepatocytes ( Figure 5-figure supplement 1C,D) . Of note, NIK overexpression still considerately attenuated STAT3 phosphorylation in IL6-stimulated IKKa-deficient hepatocytes, compared with GFP overexpression ( Figure 5-figure supplement 1D ). These findings suggest that hepatic NIK suppresses the JAK2/STAT3 pathway, and possibly liver regeneration, by both IKKadependent and IKKa-independent mechanisms.
Deficiency of hepatic NIK accelerates liver regeneration in mice with hepatotoxin-induced liver injury
Hepatic NIK is highly activated in mice and humans with chronic liver disease (Sheng et al., 2012; Shen et al., 2014) , raising the possibility that hepatic NIK might impair liver regeneration in these disease conditions. To model chronic liver disease, we treated NIK Dhep and NIK f/f male mice with 2-acetylaminofluorene (AAF), a hepatotoxin (Laishes and Rolfe, 1981) , for 10 days prior to PHx. Liver cell proliferation was assessed at 48 hr post-PHx. AAF treatment considerably increased hepatic levels of NF-kB2 p52 in wild type mice, indicative of NIK activation ( Figure 6A ). Baseline levels of proliferating Ki67 + hepatocytes in the resected liver (<2%) were comparable between NIK f/f and NIK Dhep mice ( Figure 6B ). PHx markedly increased hepatocyte proliferation rates in NIK f/f mice, which was substantially inhibited by AAF pretreatment ( Figure 6C,D) . Remarkably, the number of Ki67 + hepatocytes was significantly higher in NIK Dhep relative to NIK f/f littermates following AAF and PHx treatments ( Figure 6C,D) . Liver to body weigh ratios were slightly higher in NIK Dhep relative to NIK f/f mice at 2 days post-PHx, but not statistically different ( Figure 6-figure supplement 1A ). As discussed above, a 2 day period may be too short for newly-generated hepatocytes to grow in size to significantly increase liver weight. Plasma ALT levels were also similar between NIK f/f and NIK Dhep mice ( Figure 6E ).
We next examined cell signaling that drives cell cycle progression. We detected baseline levels of phosphorylation of hepatic STAT3 in NIK Dhep but not NIK f/f mice after AAF pretreatment ( Figure 6F ).
PHx stimulated STAT3 phosphorylation in both NIK Dhep and NIK f/f mice, but to a substantially higher Figure 6F ). Baseline hepatic cyclin D1 levels were undetectable in both NIK Dhep and NIK f/f mice pretreated with AAF, and PHx increased cyclin D1 levels to a higher extent in NIK Dhep than in NIK f/f mice ( Figure 6F ). Together, these data support the notion that abnormal activation of hepatic NIK contributes to hepatotoxin-induced impairment in liver regeneration.
Inactivation of hepatic NIK increases reparative hepatocyte proliferation in mice with NAFLD
NAFLD is associated with both arrest of hepatocyte proliferation and upregulation of hepatic NIK (Richardson et al., 2007; Inaba et al., 2015; Sheng et al., 2012; Shen et al., 2014; Collin de l'Hortet et al., 2014) , prompting us to test if elevated hepatic NIK is responsible for impairment in liver regeneration under the disease conditions. To model NAFLD, we placed NIK Dhep and NIK f/f mice on a high fat diet (HFD) for 10 weeks. Both NIK Dhep and NIK f/f mice similarly developed liver steatosis, as assessed by liver triacylglycerol (TAG) levels ( Figure 7A ). HFD feeding increased hepatic NF-kB2 p52 levels, indicative of NIK activation ( Figure 7B ). To assess liver regeneration, we performed PHx after HFD feeding for 10 weeks. Hepatocyte proliferation was assessed at 48 hr post-PHx by staining liver sections with anti-Ki67 antibody ( Figure 7C ). Baseline levels of hepatocyte proliferation in the resected liver were comparable between NIK Dhep and NIK f/f mice ( Figure 7D ). PHx markedly increased hepatocyte proliferation in chow-fed NIK f/f mice, which was substantially inhibited by HFD feeding ( Figure 7E) . Importantly, number of proliferating Ki67 + hepatocytes was significantly higher in NIK Dhep than in NIK f/f littermates after HFD feeding ( Figure 7E ). Liver/body weight ratios were slightly higher in NIK Dhep relative to NIK f/f mice at 2 days post-PHx, but not statistically different (Figure 6-figure supplement 1B ). This modest difference can be explained by the short duration that limits the capacity of newly-generated hepatocytes to significantly grow in size and increase liver weight. Plasma ALT levels were comparable between NIK Dhep and NIK f/f littermates under both basal and PHx conditions ( Figure 7F ). We further explored liver mitogenic pathways in these mice. Baseline STAT3 phosphorylation levels in the resected liver were similar between NIK Dhep and NIK f/f mice fed HFD; however, liver STAT3 phosphorylation increased to a considerably higher level in NIK Dhep relative to NIK f/f mice at 48 hr post-PHx ( Figure 7G ). Hepatic cyclin D1 levels were also higher in NIK Dhep than in NIK f/f mice postPHx ( Figure 7G ). These data suggest that aberrant activation of hepatic NIK suppresses hepatocyte proliferation and liver regeneration in NAFLD at least in part by inhibiting the JAK2/STAT3 pathway.
Discussion
Reparative hepatocyte proliferation plays a pivotal role in the maintenance of liver homeostasis and integrity by supplying new hepatocytes to replace lost ones. Liver regeneration impairment is likely involved in chronic liver disease. In this work, we identified hepatic NIK and IKKa as unrecognized suppressors of liver regeneration; moreover, NIK inhibits hepatocyte proliferation at least in part by activating IKKa. We previously demonstrated that hepatic NIK is aberrantly activated in mice and humans with chronic liver disease (Sheng et al., 2012; Shen et al., 2014) . Our current results show that elevated activation of hepatic NIK pathways impairs liver regeneration, likely contributing to liver disease progression. We found that hepatocyte-specific ablation of NIK or IKKa substantially increases hepatocyte proliferation in NIK Dhep or IKKa Dhep mice following PHx. Accordingly, liver regeneration rates were higher both in NIK Dhep relative to NIK f/f littermates and in IKKa Dhep relative to IKKa f/f mice. We observed that both NIK and IKKa bound to JAK2 and substantially inhibited the ability of JAK2 to phosphorylate STAT3. Consistently, hepatocyte-specific ablation of either NIK or IKKa substantially increased phosphorylation of hepatic JAK2 and STAT3 in mice post-PHx. IKKa deficiency decreased the ability of NIK to suppress the JAK2/STAT3 pathway in hepatocytes, confirming that IKKa acts downstream of NIK. However, NIK overexpression still inhibited the JAK2/STAT3 pathway in IKKadeficient hepatocytes, suggesting that hepatic NIK is able to suppress the JAK2/STAT3 pathway by an additional IKKa-independent mechanism. The JAK2/STAT3 pathway is known to drive hepatocyte proliferation, which is indispensable for liver regeneration (Wang et al., 2011; Shi et al., 2017; Riehle et al., 2008; Cressman et al., 1996) . Therefore, hepatic NIK and IKKa inhibit liver regeneration at least in part by suppressing the JAK2/STAT3 pathway. Mounting evidence shows that hepatic NIK is aberrantly activated in chronic liver disease, likely due to liver inflammation and hepatocellular stress (Sheng et al., 2012; Shen et al., 2014) . We modeled chronic liver disease by chronically treating mice with hepatotoxin AAF or placing them on HFD. We found that hepatocyte-specific inactivation of NIK substantially increases the ability of PHx to stimulate hepatocyte proliferation in both AAF-treated mice and HFD-fed NIK Dhep mice. Consistently, in mice pretreated with AAF or HFD, ablation of hepatic NIK increased phosphorylation of both hepatic JAK2 and STAT3 post-PHx. It is worth mentioning that NIK in nonparenchymal cells (e.g. immune cells) also contributes to obesity-associated liver steatosis . These observations raise the possibility that in chronic liver disease, NIK in Kupffer cells/macrophages, and possibly other nonparenchymal cells, may indirectly inhibit reparative hepatocyte replication by a paracrine mechanism. Collectively, our results provide proof of concept evidence supporting the notion that aberrant hepatic NIK impairs reparative hepatocyte replication, thereby contributing to liver disease progression.
In conclusion, we have identified hepatic NIK and IKKa as unrecognized suppressors of reparative hepatocyte replication. NIK and IKKa suppress liver regeneration at least in part by inhibiting the hepatic JAK2/STAT3 pathway. Our findings suggest that pharmacological inhibition of hepatic NIK or IKKa may provide a new therapeutic strategy for liver disease treatment. Antibodies and animals Antibodies were described in the key resources table. Animal experiments were conducted following the protocols approved by the University of Michigan Institutional Animal Care and Use Committee (IACUC). We generated NIK f/f , NIK Dhep , and IKKa Dhep mice (C57BL/6 background). IKKa f/f mice (C57BL/6 background) were provided by Dr. Yinling Hu (the Inflammation and Tumorigenesis Section, National Cancer Institute). Albumin-Cre mice (C57BL/6 background) were from the Jackson laboratory (Bar Harbor, ME). Mice were housed on a 12 hr light-dark cycle and fed a normal chow diet (9% fat; Lab Diet, St. Louis, MO) or a HFD (60% fat in calories; D12492, Research Diets, New Brunswick, NJ) ad libitum with free access to water.
Materials and methods
PHx models
We followed published 2/3 PHx protocols (Mitchell and Willenbring, 2008) . Briefly, NIK f/f , NIK Dhep , IKKa f/f , and IKKa Dhep male mice (8-10 wks,) were anesthetized with isoflurane, followed by a ventral midline incision. The median and left lateral lobes (70% of the liver) were resected by pedicle ligations. Mice were euthanized after PHx, and tissues were harvested for histological and biochemical analyses. Mice were introperitoneally injected, 12 hr before euthanization, with BrdU (40 mg/kg body weight, ip) to label proliferating cells. A separate cohort was fed a HFD for 10 weeks prior to PHx. An additional cohort was treated with hepatotoxin 2-acetylaminofluorene (AAF) (10 mg/kg body weight, gavage) daily for 10 days prior to PHx.
Immunostaining
Liver frozen sections were prepared using a Leica cryostat (Leica Biosystems Nussloch GmbH, Nussloch, Germany), fixed in 4% paraformaldehyde for 30 min, blocked for 3 hr with 5% normal goat serum (Life Technologies) supplemented with 1% BSA, and incubated with the indicated antibodies at 4˚C overnight. The sections were incubated with Cy2 or Cy3-conjugated secondary antibodies.
Cell cultures, transient transfection, and adenoviral transductions
Primary hepatocytes were prepared from mouse liver using type II collagenase (Worthington Biochem, Lakewood, NJ) and grown on William's medium E (Sigma) supplemented with 2% FBS, 100 units ml À1 penicillin, and 100 mg ml À1 streptomycin, and infected with adenoviruses as described previously (Zhou et al., 2009 ). HEK293 cells were grown at 37˚C in 5% CO 2 in DMEM supplemented with 25 mM glucose, 100 U ml À1 penicillin, 100 mg ml À1 streptomycin, and 8% calf serum. For transient transfection, cells were split 16-20 hr before transfection. Expression plasmids were mixed with polyethylenimine (Sigma, St. Louis, MO) and introduced into cells. The total amount of plasmids was maintained constant by adding empty vectors. Cells were harvested 48 hr after transfection for biochemical analyses.
Immunoprecipitation and immunoblotting
Cells or tissues were homogenized in a L-RIPA lysis buffer (50 mm Tris, pH 7.5, 1% Nonidet P-40, 150 mm NaCl, 2 mm EGTA, 1 mm Na 3 VO 4 , 100 mm NaF, 10 mm Na 4 P 2 O 7 , 1 mm benzamidine, 10 mg ml À1 aprotinin, 10 mg ml À1 leupeptin, 1 mm phenylmethylsulfonyl fluoride). Tissue samples were homogenized in lysis buffer (50 mM Tris, pH 7.5, 1% Nonidet P-40, 150 mM NaCl, 2 mM EGTA, 1 mM Na 3 VO 4 , 100 mM NaF, 10 mM Na 4 P 2 O 7 , 1 mM benzamidine, 10 mg/ml aprotinin, 10 mg/ml leupeptin; 1 mM phenylmethylsulfonyl fluoride). Proteins were separated by SDS-PAGE and immunoblotted with the indicated antibodies.
Real-time quantitative PCR (qPCR) and ROS assays
Total RNAs were extracted using TRIzol reagents (Life technologies). Relative mRNA abundance of different genes was measured using SYBR Green PCR Master Mix (Life Technologies, 4367659). Liver lysates were mixed with a dichlorofluorescein diacetate fluorescent (DCF, Sigma, D6883) probe (5 mM) for 1 hr at 37˚C. DCF fluorescence was measured using a BioTek Synergy 2 Multi-Mode Microplate Reader (485 nm excitation and 527 nm emission).
Statistical analysis
Data were presented as means ± sem. Differences between two groups were analyzed using twotailed Student's t tests. p<0.05 was considered statistically significant. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. Data availability All data generated or analysed during this study are included in the manuscript and supporting files.
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